

***SELP* Asp603Asn and severe thrombosis in COVID-19 males: implication for anti P-selectin monoclonal antibodies treatment**

Key points:

- ° The functional polymorphism rs6127 (p.Asp603Asn) in the testosterone-regulated *SELP* gene associates with COVID-19 severity and thrombosis.
- ° Conditions with decreased testosterone (old males), or decreased testosterone efficacy (*AR* gene polyQ ≥ 23) strengthen the association.

Short title: Asp603Asn P-selectin polymorphism and severe COVID-19

Chiara Fallerini, PhD^{1,2}, Sergio Daga, PhD^{1,2}, Elisa Benetti, MS², Nicola Picchiotti, MS^{3,4}, Kristina Zguro, MS², Francesca Catapano, BSc^{1,2}, Virginia Baroni, BSc^{1,2}, Simone Lanini⁵, Alessandro Bucalossi, MD⁶, Giuseppe Marotta⁶, Margherita Baldassarri, MD^{1,2}, Francesca Fava, MD^{1,2,7}, Giada Beligni^{1,2}, Laura Di Sarno^{1,2}, Diana Alaverdian^{1,2}, Maria Palmieri, PhD^{1,2}, Susanna Croci, PhD^{1,2}, Andrea M. Isidori⁸, Simone Furini, PhD², Elisa Frullanti, PhD^{1,2,8}, GEN-COVID Multicenter Study, Alessandra Renieri, MD, PhD^{1,2,7^}, Francesca Mari, MD, PhD^{1,2,7}

- 1) Medical Genetics, University of Siena, Italy
- 2) Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Italy
- 3) Department of Mathematics, University of Pavia, Pavia, Italy
- 4) University of Siena, DIISM-SAILAB, Siena, Italy
- 5) National Institute for the Infectious Diseases "L. Spallanzani," Rome, Italy.
- 6) Stem Cell Transplant and Cellular Therapy Unit, University Hospital, Siena, Italy
- 7) Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Italy
- 8) Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy

^ Corresponding author:
Professor Alessandra Renieri
Medical Genetics Unit
University of Siena
Policlinico Le Scotte
Viale Bracci, 2, 53100 Siena, Italy
Phone: +39 0577 233303
Fax: +39 0577 233325
E.mail: alessandra.renieri@unisi.it

Words count for abstract: 185
Word counts for text: 1198
Figure/table count: 2
Reference count: 28

Abstract

Thromboembolism is a frequent cause of severity and mortality in COVID-19. However, the etiology of this phenomenon is not well understood. A cohort of 1,186 subjects, from the GEN-COVID consortium, infected by SARS-CoV-2 with different severity were stratified by sex and adjusted by age. Then, common coding variants from whole exome sequencing were mined by LASSO logistic regression. The homozygosity of the cell adhesion molecule P-selectin gene (*SELP*) rs6127 (c.1807G>A; p.Asp603Asn) which increases platelet activation is found to be associated with severity in the male subcohort of 513 subjects (Odds Ratio= 2.27, 95% Confidence Interval 1.54-3.36). As the *SELP* gene is downregulated by testosterone, the odd ratio is increased in males older than 50 (OR 2.42, 95% CI 1.53-3.82). Asn/Asn homozygotes have increased D-dimers values especially when associated with poly Q_{≥23} in the androgen receptor (*AR*) gene (OR 3.26, 95% CI 1.41-7.52). These results provide

a rationale for the repurposing of antibodies against P-selectin as adjuvant therapy in rs6127 male homozygotes especially if older than 50 or with impaired *AR* gene.

INTRODUCTION

Since its onset in early 2020, the global pandemic of coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has posed a multitude of challenges and triggered intensive research on the disease and the virus. However, a lot of questions still remain unanswered, especially those regarding its heterogeneity of clinical manifestations and the appropriate therapeutic strategies.

It is now widely recognized that COVID-19 is a systemic disease¹ characterized by dysregulation of the immune system and presence of a hypercoagulable state². COVID-19 severe patients show coagulation abnormalities with increased incidence of arterial thrombosis and mortality has been shown to correlate with elevated levels of both interleukin-6 (IL-6) and D-dimer^{2,3}. These values have often been reported accompanied by a relatively modest decrease in platelet count⁴, and prolongation of the prothrombin time³.

Genetic bases of this prothrombotic susceptibility remain until now elusive, despite the fact that it is evident that phenotypic variability associated with the viral infection is obviously also due to host genetic factors. Some rare variants of genes involved in adaptive immunity have been identified by us and others in Mendelian forms of COVID-19⁵⁻⁷. Among common genetic factors, the protective role of the zero blood group has been linked to destabilization of the von Willebrand factor and protection from thrombosis⁸. We have shown that longer polyQ repeats (≥ 23) in the androgen receptor gene (*AR*) predisposes to severe COVID-19 outcome due to reduced anti-inflammatory and anti-thrombotic effect of testosterone⁹.

The testosterone inhibited P-selectin (*SELP*) gene encodes a cell adhesion molecule that is stored in the alpha-granules of platelets and in Weibel-Palade bodies of endothelial cells. It mediates the interaction of activated platelets on endothelium with leukocytes playing a key role in the thrombotic process^{10,11}. A significantly increased P-selectin concentration in plasma samples of severe COVID-19 patients compared to healthy controls, together with other prothrombotic biomarkers has been recently demonstrated^{12,13}.

Among *SELP* variants, the Asp603Asn functional polymorphism (rs6127; c.1807G>A) - previously reported as Asp562Asn or Asp541Asn - has been associated with risk of thrombotic disease, tissue damage in diabetes, abortion, as well as myocardial infarction¹⁴⁻¹⁸. The polymorphism is located within the consensus repeat domain of the *SELP* protein¹⁹, and it has been shown to affect the binding of P-selectin to its ligand (PSGL-1) on leukocytes, resulting in a protein that is more efficient at recruiting leukocytes to the endothelium¹⁶.

Here, we applied Ordered Logistic Regression (OLR) analysis on clinical data and LASSO logistic regression on WES data within our prospectively recruited GEN-COVID cohort and identified *SELP* as a key player for severity and thromboembolism in severe COVID-19.

MATERIAL AND METHODS

A cohort of 1,186 SARS-CoV-2-infected subjects was recruited during the first pandemic wave within the Italian GEN-COVID Study (<https://sites.google.com/dbm.unisi.it/gen-covid>)¹. ORL model was applied to the clinical WHO gradings, stratified by sex and adjusted by age, as described elsewhere²⁰. The male subset consists of 513 COVID-19 male patients: 236 severe COVID-19 patients (cases) and 277 SARS-CoV-2 PCR-positive oligo-asymptomatic subjects (controls). WES with at least

97% coverage at 20x was performed using the NovaSeq6000 System (Illumina, San Diego, CA, USA) as previously described¹. WES data were represented in a binary mode on a gene-by-gene basis²⁰. LASSO logistic regression model was applied to a synthetic boolean representation under recessive model of genetic combinations²⁰. Association was confirmed by Chi Square Test. Longitudinal laboratory values were represented by linear graphs. Differences were assessed by Mann–Whitney test and displayed by box plots. Statistical procedures were carried out using R packages.

RESULTS AND DISCUSSION

Within the Italian GEN-COVID cohort, we tested different combination of coding polymorphisms of human genes at homozygous state and found that the Asp603Asn polymorphism of the *SELP* gene correlate with severity in the subcohort of males (**Figure 1, panel A**)^{1,20}. The genotypic frequencies of the polymorphism in cases and controls were confirmed to be in Hardy-Weinberg equilibrium; the minor allele frequency in our cohort was similar to that reported in the European (non-Finnish) population in the gnomAD database (16.4% versus 15.9%) (<https://gnomad.broadinstitute.org/>).

We reasoned that the hyper-inflammatory and hyper-thrombotic state, due to viral injury of the vascular endothelium, leads to the release of P-selectin by activated platelets, driving thrombosis and vascular inflammation especially in those individuals with enhanced P-selectin activities due a double copy of Asparagine in position 603 without any other additional coding polymorphisms¹⁶. These results are in line with the demonstration that SARS-CoV-2 induces thrombosis by binding to ACE2 on platelets and subsequent integrin α IIb β 3 activation and P-selectin expression²¹, and that P-selectin soluble isoform is increased in thrombosis^{10,11} and severe COVID-19^{12,13}.

The association between Asp603Asn polymorphism (rs6127) in homozygous state, in absence of other coding polymorphisms, and severity is quite strong with an OR 2.27 in males (95% CI, 1.54 to 3.36; p-value 2.8×10^{-5} , **Table 1a**). We reasoned that, since *SELP* transcription is inhibited by androgens²², the strength of the association should increase with age. Indeed, in males aged ≥ 50 years we found an increased OR of 2.42 (95% CI, 1.53 to 3.82; p-value 1.19×10^{-4} , **Table 1b**). While the significance is, instead, lost in young males (<50 years), (data not shown p= 1.1×10^{-1}).

In a subset of 52 severely affected hospitalised males, 4 main laboratory parameters indicating thrombosis (D-dimer, platelets and LDH) and severity (lymphocytes) were longitudinally followed (**Figure 1, Panel B-E**). We observed that the maximum pick, over 10 times of the normal value, was exclusive of Asp/Asn and Asn/Asn genotypes and older patients (**Figure 1, Panel B-E**). The pick timing was earlier in Asn/Asn (median 7.5 days from infection) than Asp/Asn (median 13.5 days from infection), (p-value = 3×10^{-2} , **Figure 1, panel F**). As the von Willebrand factor (vWF) is a downstream effector for clotting, the non-zero blood group, associating with more stable vWF, also correlate with higher D-dimer and LDH values (**Figure 1, panel G-H**), in agreement with previous reports⁸.

Given the higher association of the *SELP* polymorphism in older males we reasoned that the *AR* poly-Q status would impact on the *SELP* genotype⁹: the combination of poly-Q polymorphism ≥ 23 with homozygous *SELP* polymorphism versus D-dimer value reached an OR of 3.26 (95% CI 1.41-7.52; p-value 3.73×10^{-3}), (**Table 1c**). This result indicates that the two polymorphisms enhance each other, and that the *SELP* Asp603Asn and the *AR* poly-Q are two factors belonging to the same puzzle contributing to thrombosis in COVID-19 in males.

Anti-*P-Selectin* monoclonal antibodies have been developed for human use: the phase 3 Inclacumab and the FDA and EMA approved Crizanlizumab. The latter is indicated to

prevent vaso-occlusive crises in patients with sickle cell disease and to decrease inflammation, blocking leucocyte and platelet adherence to the vessel wall²³⁻²⁵. A general clinical trial to test the efficacy and safety of Crizanlizumab in patients hospitalized with COVID-19 is ongoing (<https://clinicaltrials.gov/ct2/show/study/NCT04435184>), in not selected patients. Clinical trials in COVID-19 hospitalised males with *SELP* rs6127 c.1807G>A p.Asp603Asn should be encouraged.

In conclusion, we identified *SELP* rs6127 polymorphism as the elusive genetic factor predisposing COVID-19 patients to thromboembolism leading to life-threatening disease. We showed that predisposition increases if the protective effect of testosterone is lost either by age or because of additional genetic factors such as poly Q_{≥23} in the *AR* gene. This knowledge provides a rationale for repurposing anti P-selectin monoclonal antibodies as personalized adjuvant therapy in men affected by COVID-19.

ACKNOWLEDGMENT

This study is part of the GEN-COVID Multicenter Study, <https://sites.google.com/dbm.unisi.it/gen-covid>, the Italian multicenter study aimed at identifying the COVID-19 host genetic bases. Specimens were provided by the COVID-19 Biobank of Siena, which is part of the Genetic Biobank of Siena, member of BBMRI-IT, of Telethon Network of Genetic Biobanks (project no. GTB18001), of EuroBioBank, and of RDCConnect. We thank the CINECA consortium for providing computational resources and the Network for Italian Genomes (NIG) <http://www.nig.cineca.it> for its support. We thank private donors for the support provided to A.R. (Department of Medical Biotechnologies, University of Siena) for the COVID-19 host genetics research project (D.L n.18 of March 17,

2020). We also thank the COVID-19 Host Genetics Initiative ([https:// www.covid19hg.org/](https://www.covid19hg.org/)), MIUR project “Dipartimenti di Eccellenza 2018-2020” to the Department of Medical Biotechnologies University of Siena, Italy and “Bando Ricerca COVID-19 Toscana” project to Azienda Ospedaliero Universitaria Senese. We also thank Intesa SanPaolo for the 2020 charity fund dedicated to the project "N. B/2020/0119 Identificazione delle basi genetiche determinanti la variabilità clinica della risposta a COVID-19 nella popolazione italiana"; the Italian Ministry of University and Research for funding within the “Bando FISR 2020” in COVID-19 and and the Istituto Buddista Italiano Soka Gakkai for funding the project “PAT-COVID: Host genetics and pathogenetic mechanisms of COVID-19” (ID n. 2020-2016_RIC_3).

AUTHORSHIP

Contribution: AR, FM and EF designed the study; CF, SD, EB, NP, KZ, FC, VB, GB, LDS, DA, SL, SC, MP, AB, GM, AMI, EF, SF analysed the data; EB, KZ, NP, SF performed statistical analysis; MB, FF and GEN-COVID Multicenter Study provided clinical data; AR and FM supervised the study and all authors edited the manuscript and approved its final version.

Conflict-of-interest disclosure: All the authors declare no competing financial interests.

Correspondence: Professor Alessandra Renieri, Medical Genetics Unit, University of Siena, Policlinico Le Scotte Viale Bracci, 2, 53100 Siena, Italy, e-mail: alessandra.renieri@unisi.it.

ETHICS APPROVAL

The study (GEN-COVID) was consistent with Institutional guidelines and approved by the University Hospital (Azienda Ospedaliero-Universitaria Senese) Ethical Review Board,

Siena, Italy (Prot n. 16929, dated March 16, 2020).

DATA AVAILABILITY STATEMENT

The data and samples referenced here are housed in the GEN-COVID Patient Registry and the GEN-COVID Biobank and are available for consultation. You may contact the corresponding author, Prof. Alessandra Renieri (e-mail: alessandra.renieri@unisi.it).

CONFLICT OF INTEREST

All the authors declare no competing financial interests.

REFERENCES

1. Daga S, Fallerini C, Baldassarri M, et al. Employing a systematic approach to biobanking and analyzing genetic and clinical data for advancing COVID-19 research. *Eur J Hum Genet.* Jan 17. doi: 10.1038/s41431-020-00793-7 (2021).
2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054-1062. doi:10.1016/s0140-6736(20)30566-3.
3. Tang N, Li D, Wang X et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost.* 2020. <https://doi.org/10.1111/jth.14768>.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395: 497–506.
5. Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science.* 2020;370(6515):eabd4570. doi:10.1126/science.abd4570.
6. van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G et al. Presence of Genetic Variants Among Young Men With Severe COVID-19. *JAMA.* 2020 Aug 18;324(7):663-673. doi: 10.1001/jama.2020.13719. PMID: 32706371; PMCID: PMC7382021.

7. Fallerini C, Daga S, Mantovani S, et al. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. *Elife*. 2021 Mar 2;10:e67569. doi: 10.7554/eLife.67569. PMID: 33650967; PMCID: PMC7987337.
8. Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med*. 2020 Oct 15;383(16):1522-1534. doi: 10.1056/NEJMoa2020283. Epub 2020 Jun 17. PMID: 32558485; PMCID: PMC7315890.
9. Baldassarri M, Picchiotti N, Fava F et al. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. *EBioMedicine*. 2021 Mar;65:103246. doi: 10.1016/j.ebiom.2021.103246. Epub 2021 Feb 26. PMID: 33647767; PMCID: PMC7908850.
10. Blann AD, Nadar SK, Lip GYH et al. The adhesion molecule P-selectin and cardiovascular disease. *Eur Heart J* 2003;24:2166–79.
11. Merten M, Thiagarajan et al. P. P-selectin and arterial thrombosis. *Z Kardiol* 2004;93:855–63.
12. Lopez-Castaneda S, García-Larragoiti N, Cano-Mendez A, et al. Inflammatory and Prothrombotic Biomarkers Associated With the Severity of COVID-19 Infection. *Clin Appl Thromb Hemost*. 2021 Jan-Dec;27:1076029621999099. doi: 10.1177/1076029621999099. PMID: 33835872; PMCID: PMC8040552.
13. Bongiovanni D, Klug M, Lazareva O, et al. SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype. *Cell Death Dis*. 2021 Jan 5;12(1):50. doi: 10.1038/s41419-020-03333-9. PMID: 33414384; PMCID: PMC7790351.
14. Ay C, Jungbauer LV, Kaider A, et al. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. *Thromb Haemost*. 2008 May;99(5):899-904. doi: 10.1160/TH07-11-0672. PMID: 18449419.
15. Volcik KA, Ballantyne CM, Coresh J, et al. Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. *Atherosclerosis*. 2007 Nov;195(1):e76-82. doi: 10.1016/j.atherosclerosis.2007.03.007. Epub 2007 Apr 8. PMID: 17420019; PMCID: PMC2175083.

16. Tregouet DA, Barbaux S, Escolano S, et al. Specific haplotypes of the P-selectin gene are associated with myocardial infarction. *Hum Mol Genet.* 2002 Aug 15;11(17):2015-23. doi: 10.1093/hmg/11.17.2015. PMID: 12165563.
17. Kaur R, Singh J, Kapoor R, et al. Association of SELP Polymorphisms with Soluble P-Selectin Levels and Vascular Risk in Patients with Type 2 Diabetes Mellitus: A Case-Control Study. *Biochem Genet.* 2019 Feb;57(1):73-97. doi: 10.1007/s10528-018-9881-6. Epub 2018 Jul 25. PMID: 30047017.
18. Dendana M, Hizem S, Magddoud K, et al. Common polymorphisms in the P-selectin gene in women with recurrent spontaneous abortions. *Gene.* 2012 Mar 1;495(1):72-5. doi: 10.1016/j.gene.2011.11.034. Epub 2011 Dec 13. PMID: 22192915.
19. Ruchaud-Sparagano MH, Malaud E, Gayet O, et al. Mapping the epitope of a functional P-selectin monoclonal antibody (LYP20) to a short complement-like repeat (SCR4) domain: use of human-mouse chimaera and homologue-replacement mutagenesis. *Biochem J* 1998; 332: 309–314.
20. Nicola Picchiotti, Elisa Benetti, Chiara Fallerini, et al. Post-Mendelian genetic model in COVID-19 medRxiv 2021.01.27.21250593; doi: <https://doi.org/10.1101/2021.01.27.2125059365563>.
21. Zhang, S., Liu, Y., Wang, X. et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. *J Hematol Oncol* 13, 120 (2020). <https://doi.org/10.1186/s13045-020-00954-7>.
22. Karolczak K, Konieczna L, Kostka T, et al. Testosterone and dihydrotestosterone reduce platelet activation and reactivity in older men and women. *Aging (Albany NY).* 2018 May 2;10(5):902-929. doi: 10.18632/aging.101438. PMID: 29723157; PMCID: PMC5990384.
23. Neri T, Nieri D, Celi A. P-selectin blockade in COVID-19-related ARDS. *Am J Physiol Lung Cell Mol Physiol.* 2020 Jun 1;318(6):L1237-L1238. doi: 10.1152/ajplung.00202.2020. PMID: 32464083; PMCID: PMC7276981.
24. Blair HA. Crizanlizumab: First Approval. *Drugs.* 2020 Jan;80(1):79-84. doi: 10.1007/s40265-019-01254-2. PMID: 31933169.
25. Agrati C, Bordoni V, Sacchi A et al. Elevated P-Selectin in Severe Covid-19: Considerations for Therapeutic Options. *Mediterr J Hematol Infect Dis.* 2021 Mar 1;13(1):e2021016. doi: 10.4084/MJHID.2021.016. PMID: 33747397; PMCID: PMC7938922.

TABLES

Table 1. Chi-square test in male cohort calculated for all ages (**Table 1a**); for age ≥ 50 years (**Table 1b**); and combination of AR poly-Q ≥ 23 and D-dimer value (**Table 1c**).

Table 1a.

Chi-square test in male cohort (all ages)

	Cases (%)	Controls (%)	<i>Marginal Row Totals</i>
Asn/Asn genotype	90 (38.14)	59 (21.30)	149
Asp/Asp and Asp/Asn genotype	146 (61.86)	218 (70.70)	364
<i>Marginal Column Totals</i>	236 (100)	277 (100)	513 (Grand total)
p-value (cases vs controls) = 2.8×10^{-5} (OR 2.27, 95% CI 1.54-3.36)			

Table 1b.

Chi-square test in males ≥ 50 years

	Cases (%)	Controls (%)	<i>Marginal Row Totals</i>
Asn/Asn genotype	73 (39.25)	40(21.05)	113
Asp/Asp and Asp/Asn genotype	113 (60.75)	150 (78.95)	263
<i>Marginal Column Totals</i>	186 (100)	190 (100)	376 (Grand total)
p-value (cases vs controls) = 1.19×10^{-4} (OR 2.42, 95% CI 1.53-3.82)			

Table 1c.

Chi-square test of combination of AR poly Q ≥ 23 and D-dimer value

	D-dimer > 5000	D-dimer < 5000	<i>Marginal Row Totals</i>
Asn/Asn and AR polyQ ≥ 23	10	19	29
Asp/Asp and Asp/Asn and AR poliQ < 23	40	248	288
<i>Marginal Column Totals</i>	50	267	317 (Grand total)
p-value = (cases vs controls) 3.73×10^{-3} (OR 3.26, 95% CI 1.41-7.52)			

FIGURES

Figure 1. Homozygous genotype Asn/Asn at the polymorphic locus Asp603Asn (rs6127) is related to severity and to D-Dimer pick.




FIGURE LEGENDS

Figure 1. Homozygous genotype Asn/Asn at the polymorphic locus Asp603Asn (rs6127) is related to severity and to D-Dimer pick

Panel A. Selection of *SELP* gene as relevant for severity. LASSO logistic regression on boolean representation of homozygous common bi-allelic polymorphism of autosomal genes in males is presented (see paper Picchiotti N. et al. 2021 for complete representations)²¹. The LASSO logistic regression model provides an embedded feature selection method within the binary classification tasks (cases vs controls). The upward histogram means positive weights,

i.e the specific variant at the specific locus (feature) contribute to severity of COVID-19.

SELP_1_homo = homozygous genotype Asn/Asn at the polymorphic locus Asp603Asn (rs6127). The downward histograms means negative weights, contributing to mildness of COVID-19. *COG3_1_homo* = homozygous genotype Ser/Ser at the polymorphic locus Leu825Ser (rs3014902). *COG3* gene encodes for a vesicle docking protein involved in viral trafficking. *TMEM221_2_homo* = homozygous genotype Ala/Ala at the polymorphic locus Thr66Ala (rs4808641). *TMEM221* gene encodes for a transmembrane protein. **Panel B-E.** Longitudinal laboratory data related to thrombosis and severity. Linear graphs of 4 laboratory values: D-dimer $\mu\text{g/L}$ (**Panel B**), platelets $10^3/\text{mmc}$ (**Panel C**), lymphocytes $10^3/\text{mmc}$ (**Panel D**), LDH UI/L (**Panel E**). As expected the Asn/Asn homozygous genotype was over-represented (36.53%). Values are reported on the Y-axis. In each graph the time point “0” (X-axis) represents the day of onset of COVID-19 symptoms. Each line represents each severe hospitalized patient (see methods). Each point represents the different time point (day) in which the different values have been measured. Patients aged ≥ 55 years are indicated in blue while patients aged < 55 years in red. From left to right patients having Asp/Asp homozygous; Asp/Asn heterozygous; and Asn/Asn homozygous genotype. Older patients only (blue) and Asp/Asn-Asn/Asn genotype only show the D-dimer pick. Accordingly, older patients of these 2 genotypes have more platelet consumption and higher LDH values. **Panel F.** The D-dimer pick is earlier in the Asn/Asn (median = 7.5 days) than the Asp/Asn genotype ($p = 3 \times 10^{-2}$ by Mann Whitney test). Box plot of patients with D-dimer values above $2000 \mu\text{g/l}$ were represented. Only Asp/Asn (light blue) and Asn/Asn (pink) genotypes are represented because patients with Asp/Asp genotype do not have the pick and do not show value above 2.000. **Panel G-H.** The non-zero group associates with higher D-dimer (**Panel G**) and LDH values (**Panel H**). Severe hospitalized patients with zero blood group =light blue; non-zero blood group =pink in box plots.

GEN-COVID Multicenter Study (<https://sites.google.com/dbm.unisi.it/gen-covid>)

Floriana Valentino^{1,2}, Gabriella Doddato^{1,2}, Annarita Giliberti^{1,2}, Rossella Tita⁷, Sara Amitrano⁷, Mirella Bruttini^{1,2,7}, Iaria Meloni^{1,2}, Anna Maria Pinto⁷, Maria Antonietta Mencarelli⁷, Caterina Lo Rizzo⁷, Francesca Montagnani^{2,8}, Miriam Lucia Carriero^{1,2}, Massimiliano Fabbiani⁸, Iaria Rancan⁸, Barbara Rossetti⁸, Mario Tumbarello^{2,8}, Elena Bargagli⁹, Laura Bergantini⁹, Miriana D'Alessandro⁹, Paolo Cameli⁹, David Bennett⁹, Federico Anedda¹⁰, Simona Marcantonio¹⁰, Sabino Scolletta¹⁰, Federico Franchi¹⁰, Maria Antonietta Mazzei¹¹, Susanna Guerrini¹¹, Edoardo Conticini¹², Luca Cantarini¹², Bruno Frediani¹², Danilo Tacconi¹³, Chiara Spertilli Raffaelli¹³, Marco Feri¹⁴, Alice Donati¹⁴, Raffaele Scala¹⁵, Luca Guidelli¹⁵, Genni Spargi¹⁶, Marta Corridi¹⁶, Cesira Nencioni¹⁷, Leonardo Croci¹⁷, Gian Piero Caldarelli¹⁸, Maurizio Spagnesi¹⁹, Paolo Piacentini¹⁹, Maria Bandini¹⁹, Elena Desanctis¹⁹, Silvia Cappelli¹⁹, Anna Canaccini²⁰, Agnese Verzuri²⁰, Valentina Anemoli²⁰, Agostino Ognibene²¹, Alessandro Pancrazi²¹, Maria Lorubbio²¹, Massimo Vaghi²², Antonella D'Arminio Monforte²³, Esther Merlini²³, Federica Gaia Miraglia²³, Mario U. Mondelli^{24,25}, Raffaele Bruno^{24,25}, Marco Vecchia²⁴, Stefania Mantovani²⁴, Serena Ludovisi^{24,25}, Massimo Girardis²⁶, Sophie Venturelli²⁶, Stefano Busani²⁶, Andrea Cossarizza²⁷, Andrea Antinori²⁸, Alessandra Vergori²⁸, Arianna Emiliozzi²⁸, Stefano Rusconi^{29,30}, Matteo Siano³⁰, Arianna Gabrieli³⁰, Agostino Riva^{29,30}, Daniela Francisci^{31,32}, Elisabetta Schiaroli³¹, Francesco Paciosi³¹, Andrea Tommasi³¹, Pier Giorgio Scotton³³, Francesca Andretta³³, Sandro Panese³⁴, Renzo Scaggiante³⁵, Francesca Gatti³⁵, Saverio Giuseppe Parisi³⁶, Francesco Castelli³⁷, Eugenia Quiros-Roldan³⁷, Melania degli Antoni³⁷, Isabella Zanella³⁸, Matteo Della Monica³⁹, Carmelo Piscopo³⁹, Mario Capasso^{40,41,42}, Roberta Russo^{40,42}, Immacolata Andolfo^{40,41}, Achille Iolascon^{40,41}, Giuseppe Fiorentino⁴³, Massimo Carella⁴⁴, Marco Castori⁴⁴, Filippo Aucella⁴⁵, Pamela Raggi⁴⁶, Carmen Marciano⁴⁶, Rita Perna⁴⁶, Matteo Bassetti^{47,48}, Antonio Di Biagio⁴⁸, Maurizio Sanguinetti^{49,50}, Luca Masucci^{49,50}, Serafina Valente⁵¹, Oreste De Vivo⁵¹, Marco Mandalà⁵², Alessia Giorli⁵², Lorenzo Salerni⁵², Patrizia Zucchi⁵³, Pierpaolo Parravicini⁵³, Elisabetta Menatti⁵⁴, Stefano Baratti⁵⁵, Tullio Trotta⁵⁶, Ferdinando Giannattasio⁵⁶, Gabriella Coiro⁵⁶, Fabio Lena⁵⁷, Domenico A. Coviello⁵⁸, Cristina Mussini⁵⁹, Giancarlo Bosio⁶⁰, Enrico Martinelli⁶⁰, Sandro Mancarella⁶¹, Luisa Tavecchia⁶¹, Mary Ann Belli⁶¹, Lia Crotti^{62,63,64,65,66}, Gianfranco Parati^{62,63}, Marco Gori^{4,67}, Chiara Gabbi⁶⁸, Maurizio Sanarico⁶⁹, Stefano Ceri⁷⁰, Pietro Pinoli⁷⁰, Francesco Raimondi⁷¹, Filippo Biscarini⁷², Alessandra Stella⁷², Marco Rizzi⁷³, Franco Maggiolo⁷³, Diego Ripamonti⁷³, Claudia Suardi⁷⁴, Tiziana Bachetti⁷⁵, Maria Teresa La Rovere⁷⁶, Simona Sarzi-Braga⁷⁷, Maurizio Bussotti⁷⁸, Simona Dei⁷⁹, Katia Capitani^{2,80}, Sabrina Ravaglia⁸¹, Rosangela Artuso⁸², Antonio Perrella⁸³, Francesco Bianchi^{2,83}, Davide Romani¹⁹, Paola Bergomi⁸⁴, Emanuele Catena⁸⁴, Riccardo Colombo⁸⁴, Sauro Luchi⁸⁵, Giovanna Morelli⁸⁵, Paola Petrocelli⁸⁵, Valentina Perticaroli^{1,2,7}, Mirjam Lista^{1,2}, Silvia Baroni⁸⁶, Francesco Vladimiro Segala⁸⁷, Alessandra Guarnaccia⁴⁹, Giuseppe Merla^{40,88}, Gabriella Maria Squeo⁸⁸

8. Dept of Specialized and Internal Medicine, Tropical and Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy

9. Unit of Respiratory Diseases and Lung Transplantation, Department of Internal and Specialist Medicine, University of Siena
10. Dept of Emergency and Urgency, Medicine, Surgery and Neurosciences, Unit of Intensive Care Medicine, Siena University Hospital, Italy
11. Department of Medical, Surgical and Neurosciences and Radiological Sciences, Unit of Diagnostic Imaging, University of Siena
12. Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Italy
13. Department of Specialized and Internal Medicine, Infectious Diseases Unit, San Donato Hospital Arezzo, Italy
14. Dept of Emergency, Anesthesia Unit, San Donato Hospital, Arezzo, Italy
15. Department of Specialized and Internal Medicine, Pneumology Unit and UTIP, San Donato Hospital, Arezzo, Italy
16. Department of Emergency, Anesthesia Unit, Misericordia Hospital, Grosseto, Italy
17. Department of Specialized and Internal Medicine, Infectious Diseases Unit, Misericordia Hospital, Grosseto, Italy
18. Laboratory Medicine Department, Misericordia Hospital, Grosseto, Italy
19. Department of Preventive Medicine, Azienda USL Toscana Sud Est, Italy
20. Territorial Scientific Technician Department, Azienda USL Toscana Sud Est, Italy
21. Laboratory Medicine Department, San Donato Hospital, Arezzo, Italy
22. Chirurgia Vascolare, Ospedale Maggiore di Crema, Italy
23. Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy
24. Division of Infectious Diseases and Immunology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
25. Department of Internal Medicine and Therapeutics, University of Pavia, Italy
26. Department of Anesthesia and Intensive Care, University of Modena and Reggio Emilia, Modena, Italy
27. Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
28. HIV/AIDS Department, National Institute for Infectious Diseases, IRCCS, Lazzaro Spallanzani, Rome, Italy
29. III Infectious Diseases Unit, ASST-FBF-Sacco, Milan, Italy
30. Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy
31. Infectious Diseases Clinic, Department of Medicine, Azienda Ospedaliera di Perugia and University of Perugia, Santa Maria Hospital, Perugia, Italy
32. Infectious Diseases Clinic, "Santa Maria" Hospital, University of Perugia, Perugia, Italy
33. Department of Infectious Diseases, Treviso Hospital, Local Health Unit 2 Marca Trevigiana, Treviso, Italy
34. Clinical Infectious Diseases, Mestre Hospital, Venezia, Italy.
35. Infectious Diseases Clinic, ULSS1, Belluno, Italy
36. Department of Molecular Medicine, University of Padova, Italy

37. Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy
38. Department of Molecular and Translational Medicine, University of Brescia, Italy; Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Italy
39. Medical Genetics and Laboratory of Medical Genetics Unit, A.O.R.N. "Antonio Cardarelli", Naples, Italy
40. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
41. CEINGE Biotecnologie Avanzate, Naples, Italy
42. IRCCS SDN, Naples, Italy
43. Unit of Respiratory Physiopathology, AORN dei Colli, Monaldi Hospital, Naples, Italy
44. Division of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
45. Department of Medical Sciences, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
46. Clinical Trial Office, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
47. Department of Health Sciences, University of Genova, Genova, Italy
48. Infectious Diseases Clinic, Policlinico San Martino Hospital, IRCCS for Cancer Research Genova, Italy
49. Microbiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Medicine, Rome, Italy
50. Department of Laboratory Sciences and Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
51. Department of Cardiovascular Diseases, University of Siena, Siena, Italy
52. Otolaryngology Unit, University of Siena, Italy
53. Department of Internal Medicine, ASST Valtellina e Alto Lario, Sondrio, Italy
54. Study Coordinator Oncologia Medica e Ufficio Flussi, Sondrio, Italy
55. Department of Infectious and Tropical Diseases, University of Padova, Padova, Italy
56. First Aid Department, Luigi Curto Hospital, Polla, Salerno, Italy
57. Local Health Unit-Pharmaceutical Department of Grosseto, Toscana Sud Est Local Health Unit, Grosseto, Italy
58. U.O.C. Laboratorio di Genetica Umana, IRCCS Istituto G. Gaslini, Genova, Italy.
59. Infectious Diseases Clinics, University of Modena and Reggio Emilia, Modena, Italy.
60. Department of Respiratory Diseases, Azienda Ospedaliera di Cremona, Cremona, Italy
61. U.O.C. Medicina, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo (MI), Italy
62. Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Milan, Italy.

63. Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
64. Istituto Auxologico Italiano, IRCCS, Center for Cardiac Arrhythmias of Genetic Origin, Milan, Italy.
65. Istituto Auxologico Italiano, IRCCS, Laboratory of Cardiovascular Genetics, Milan, Italy.
66. Member of the European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart
67. University Cote d'Azur, Inria, CNRS, I3S, Maasai
68. Independent Medical Scientist, Milan, Italy
69. Independent Data Scientist, Milan, Italy
70. Department of Electronics, Information and Bioengineering (DEIB), Politecnico di Milano, Milano, Italy
71. Scuola Normale Superiore, Pisa, Italy
72. CNR-Consiglio Nazionale delle Ricerche, Istituto di Biologia e Biotecnologia Agraria (IBBA), Milano, Italy.
73. Unit of Infectious Diseases, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy
74. Fondazione per la ricerca Ospedale di Bergamo, Bergamo, Italy
75. Direzione Scientifica, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
76. Istituti Clinici Scientifici Maugeri IRCCS, Department of Cardiology, Institute of Montescano, Pavia, Italy.
77. Istituti Clinici Scientifici Maugeri, IRCCS, Department of Cardiac Rehabilitation, Institute of Tradate (VA), Italy.
78. Cardiac Rehabilitation Unit, Fondazione Salvatore Maugeri, IRCCS, Scientific Institute of Milan, Milan, Italy.
79. Health Management, Azienda USL Toscana Sudest, Tuscany, Italy.
80. Core Research Laboratory, ISPRO, Florence, Italy
81. IRCCS C. Mondino Foundation, Pavia, Italy
82. Medical Genetics Unit, Meyer Children's University Hospital, Florence, Italy
83. Department of Medicine, Pneumology Unit, Misericordia Hospital, Grosseto, Italy.
84. Department of Anesthesia and Intensive Care Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Polo Universitario, University of Milan, Milan
85. Infectious Disease Unit, Hospital of Lucca , Italy.
86. Department of Diagnostic and Laboratory Medicine, Institute of Biochemistry and Clinical Biochemistry, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
87. Clinic of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
88. Laboratory of Regulatory and Functional Genomics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (Foggia), Italy

